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To better understand human health and disease, researchers create a wide variety of mouse
models that carry human DNA. With recent advances in genome engineering, the targeted
replacement of mouse genomic regions with orthologous human sequences has become
increasingly viable, ranging from ﬁnely tuned humanisation of individual nucleotides and
amino acids to the incorporation of many megabases of human DNA. Here, we examine
emerging technologies for targeted genomic humanisation, we review the spectrum of
existing genomically humanised mouse models and the insights such models have provided,
and consider the lessons learned for designing such models in the future.
Genetically modiﬁed mice facilitate the analysis of gene function and regulation, as well asthe dissection of disease mechanisms. Transgenic mice carrying human complementaryDNAs (cDNAs) or mini-genes at non-endogenous loci have been around for decades
(herein called ‘classic transgenics’)1, as have gene-targeted mice in which changes are made to
speciﬁc DNA sequences in the mouse genome. Researchers increasingly combine these
approaches and turn to the targeted genomic humanisation of mice, creating ‘knock-in’ mouse
models in which a mouse sequence is replaced by the human orthologous DNA2. Compared
with the thousands of classic transgenic mouse strains that mostly carry human DNA as ran-
domly inserted, multicopy transgenes, the number of targeted genomically humanised mouse
strains is low (Tables 1 and 2). Such mice are designed to have greater physiological relevance
than their classic transgenic counterparts, which includes maintaining the correct genomic
context of a gene of interest to preserve physiological expression levels and correct spatio-
temporal expression patterns. Where non-coding human sequences are incorporated, human-
speciﬁc regulation and human gene splice isoforms may be maintained. In addition, the
translated protein is expected to display the unique biochemical properties of the human gene,
including potentially unique deleterious properties when mutated.
Genomically humanised mouse strains with physiological levels of gene expression tend to
have slower, milder phenotypes than transgenic overexpression models. However, these gene-
targeted animals avoid overexpression artefacts, ectopic expression, and mutations resulting
from random integration3,4 that can arise in transgenic models. Endogenous expression levels
are particularly important when modelling dosage-sensitive genes, such as the RNA binding
proteins C9orf725, TARDBP (Tar DNA-binding protein that encodes TDP-43)6,7 or FUS (fused
in sarcoma)8,9. Mutations in these genes can be causative for the neurodegenerative disease
amyotrophic lateral sclerosis (ALS), which is characterised by progressive motor neuron loss and
paralysis. In contrast, overexpression of the human wild-type FUS alone is sufﬁcient to cause
motor neuron degeneration and other deﬁcits in transgenic mice, thereby limiting the study of
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pathogenic mutations10 and making it necessary to tightly control
gene dosage in these animal models.
Thus, genomically humanised mice offer reﬁned models of
human biology and pathology, as well as models for testing
small molecule drug therapies, antibody therapeutics11, and
gene therapies such as antisense oligonucleotides12, as we will
discuss below.
As well as gaining biological insight, by analysing existing
genomically humanised mice researchers are also gathering data
for future genomic humanisation design and strategy—to guide
decisions with potentially far reaching consequences on pheno-
type. Here, we ﬁrst consider the biological, pathomechanistic and
translational insights that have been gained from genomically
humanised mice, and then we look at lessons learned so far which
may inﬂuence future humanisation strategies. New technologies
and resources (Box 1 and Fig. 1) are changing researchers’ abil-
ities to genomically humanise the mouse, but they will only be
successful if they are efﬁcient, reliable, and reproducible and
without signiﬁcant off-target effects.
Insights from humanised mouse models
Consider the question asked. It is possible to humanise indivi-
dual base pairs and thus codons within a mouse gene to deter-
mine which amino acids are critical for the function or pathology
under investigation. Experimenters can also choose a technically
more challenging strategy of humanising entire exons, genes
or even chromosomes, should the problem at hand not be
addressable by smaller genomic alterations. Now that creating
genomically humanised mice is becoming more straight forward
(although still not routine), the questions these models are meant
to address need to be clear a priori.
Humanisation of speciﬁc amino acids. Individual codon(s) for a
protein of interest can be humanised to determine whether the
encoded amino acid has a critical impact on function. An early
example comes from an investigation of the evolution of human
communication: Foxp2hum mice express a FOXP2 protein that
has two ‘human’ amino acids that normally are not present in
mouse FOXP2 (substitutions T302N and N324S). These residues
are thought to have been positively selected during human evo-
lution, possibly because of enhancing effects on speech and lan-
guage13. Foxp2hum mice have an intriguing gain-of-function
phenotype, showing altered behavioural learning dynamics and
increased corticostriatal synaptogenesis, which is opposite to the
phenotype observed in Foxp2 null mice. Thus, these ﬁnely
humanised animals are helping to shed light on evolutionary
adaptations of the human brain potentially required for the
acquisition of speech capabilities14,15.
Another example of humanising speciﬁc codons to recreate
human protein chemistry and to study the effects of mutation
comes from research on Alzheimer’s disease (AD). In humans,
the APP (amyloid precursor protein) gene, when mutated or
present in three copies, can cause early-onset AD, which involves
the deposition of the central Aβ peptide portion of the APP
Table 1 Examples of partial and smaller scale genomically humanised mice created for different investigations




Antibodies with human immunoglobulin kappa (light chain) constant
regions
0.5 kb HR in ES cells 126
IGHG1 constant
region
Antibodies with human immunoglobulin gamma-1 (heavy chain)
constant regions
2.1 kb HR in ES cells 127
FOXP2 Humanising 2 human-speciﬁc residues (related to human speech) 2 bp HR in ES cells 13
APP Humanising 3 residues in Aβ domain plus human
mutations (Alzheimer's disease)
3–7 bp HR in ES cells 19–21
APOE Humanising 1 residue critical to human APOE4
biochemistry (Alzheimer's and cardiovascular disease)
1 bp HR in ES cells 26
TP53 (p53) Humanising core DNA-binding domain plus human
mutations (cancer)
2.8 kb HR in ES cells 30–32
BDNF Modelling 2 human variant residues (psychiatric disorders) 274 bp HR in ES cells 33
OPRM1 Humanising exon 1, with one of two human polymorphic
variants (alcoholism)
0.7 kb HR in ES cells 35
AR Humanising exon 1 including Q-tract expansions (spinal bulbar
muscular atrophy)
1.6 kb HR in ES cells 75,81,82
HTT Humanising exon 1 including Q-tract expansions (Huntington
disease)
250–500 bp HR in ES cells 83–92
TNFSF11 Humanising single exon; target of monoclonal antibody drug (bone
disorders)
0.4 kb HR in ES cells 37
FUS Recapitulating FUS splice site mutation (‘delta14’), plus human
frameshifted C-terminus (ALS)
1 bp+ 9 bp HR in ES cells 8
IKAP Humanising exon 20+ ﬂanking introns, including human
mutation (familial dysautonomia)
1.5 kb HR in ES cells 38
FKTN Humanising exon 10 ± human-speciﬁc SVA retrotransposon
insertion (Fukuyama muscular dystrophy)
6+ 3 kb RMCE in ES cells 93
PRNP Humanising prion protein gene with mutation, minus signal
peptide (prion diseases)
0.8 kb HR in ES cells 103
CTLA4 Humanising gene minus signal peptide, to study anti-human CTLA4
antibody efﬁcacy (cancer)
3.2 kb HR in ES cells 104




To model lipid-functional non-coding human variant 5 bp CRISPR/Cas9-assisted
HR in zygotes
122
All mice are cited in the text
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Table 2 Examples of whole gene and larger-scale genomically humanised mice created for different investigations
Human gene/locus Detail Human KI size Technology References
Whole gene humanisation
APOE APO-E2, -E3, -E4 human variants (Alzheimer's
and cardiovascular disease)
4.1 kb HR in ES cells 39–41
IL3, TPO, CSF1, CSF2, IL15,
SIRPA
Supporting the human cellular component of
chimaeric animals with a human immune system
in immunodeﬁcient mice
8.5–17.5 kb HR in ES cells 44–48
C5AR1 To generate and study anti-human C5AR1 antibody
efﬁcacy (inﬂammation)
1 kb HR in ES cells 49
PXR, CAR Xenobiotic sensors; predicting human drug responses 4.3 kb and 7 kb HR in ES cells 52,53
GCGR Humanising target of monoclonal antibody drug
(diabetes)
4.7 kb HR in ES cells 62
SIRPA and CYP2D6 Testing ssODN-mediated end joining 199.5 and 6.2
kb
ssODN-mediated end
joining in rat zygotes
124
KMT2D Human cancer gene KI; testing CRISPR/Cas9-assisted
HR in ES cells and homology arm lengths
42 kb CRISPR/Cas9-
assisted HR in ES
cells
128
RHO Whole Rhodopsin gene plus GFP tag (retinal
degeneration)
7.4 kb Both HR and RMCE
in ES cells
106
Humanising large loci and gene clusters
IGH and IGK variable regions Antibodies with human variable regions 2.6+ 3Mb Iterative HR in ES
cells
56,57
IGH, IGK, and IGL variable
regions
Antibodies with human variable regions 917+ 838+
932 kb
S-RMCE in ES cells 55
α globin cluster Proof-of-principle for large humanisation and to
study α globin gene expression
117 kb RMGR 58
β globin genes To study β thalassaemia 8.7–11.7 kb HR in ES cells 94,97–99
CYP3A4/CYP3A7 To study cytochrome P450-mediated drug metabolism ~100 kb RMCE in ES cells 51
Transchromosomic mice
Chromosome 21 Transchromosomic mouse model for Down syndrome 42Mb MMCT 54,60,61,70,71,107
Immunoglobulin loci
transchromosomic mice
Transchromosomic mouse model for human
monoclonal antibody production
1.5+ 2Mb MMCT 102,129
All mice are cited in the text
Box 1 Technology old and new
Classical DNA targeting using plasmid vectors and homologous recombination (HR) in mouse embryonic stem (ES) cells has been the predominant
technology to date to create genomically humanised knock-in mice (Fig. 1a), applied successfully to humanise loci < 15 kb (Tables 1 and 2), but no larger
because of constraints on the insert size of plasmids used for targeting vectors. Among the earliest results were mice created to produce partially
humanised antibodies by targeted humanisation of the mouse immunoglobulin kappa (light chain) and gamma-1 (heavy chain) constant regions126,127.
With the development of new vectors that carry tens of kb or more of insert DNA, such as bacterial artiﬁcial chromosomes (BACs), yeast artiﬁcial
chromosome (YACs), human artiﬁcial chromosome (HACs) and mammalian artiﬁcial chromosomes (MACs), introducing much larger regions of
human sequence became possible. BAC vectors combined with ES cell technologies have been used to humanise whole genes, gene clusters and even
megabase-sized loci, via large-scale HR (Fig. 1a). Alternatively, recombinase enzymes and their short site-speciﬁc recombination sequences have been
exploited for ‘recombinase-mediated cassette exchange’ (RMCE; Fig. 1b) and ‘recombinase-mediated genomic exchange’ (RMGE) strategies55–58.
While these methods have worked well, new CRISPR-based technologies for knocking-in exogenous DNA are changing the research landscape, albeit
with potential off-target effects130. For example, CRISPR/Cas9-assisted HR in ES cells improves targeting efﬁciency, reducing the time and resources
required to screen ES cell clones. This method was used to assess the optimal length of homology arms required for HR and to create a new strain of
mice in which the Kmtd2 (lysine (K)-speciﬁc methyltransferase 2D) gene was replaced by its ~ 42 kb genomic human orthologue (KMTD2), from the
methionine start codon to the stop codon128.
Targeting with CRISPR/Cas9 is developing rapidly, and is increasing our capacity for genomic humanisation of rodent genomes. CRISPR/Cas9-assisted
HR in zygotes, using a single-stranded oligodeoxynucleotide (ssODN) as a repair template (also known as ‘easiCRISPR’), is sufﬁcient for efﬁcient editing
in zygotes without selection and therefore without genomic scarring. This has great potential for introducing pathogenic and other changes into large
humanised regions, or for humanising small genomic regions: the current size limit for ssODN donors is ~ 2 kb, although this boundary is constantly
challenged131,132 (Fig. 1c).
CRISPR/Cas9 combined with ssODN-mediated end joining is a striking new method for knocking-in long sequences directly to zygotes without the need
to clone homology arms. Instead, a pair of short ssODNs harbouring short regions of homology, split between the donor template and target site, is
used (Fig. 1d). This method was applied to knock-in 200 kb of human DNA including the SIRPA (signal-regulatory protein alpha) locus from a BAC
vector, while removing the rat Sirpa homologous region, and in a separate experiment, to replace 58 kb of the rat Cyp2d (cytochrome P450, 2d) cluster
with a 6.2 kb human CYP2D6 gene124.
Finally, the mouse genome can also be genomically humanised by adding entire human chromosomes, with the purpose of modelling the complexities
of human aneuploidy disorders, such as Down syndrome, which arises from trisomy of chromosome 21. This can be achieved by microcell-mediated
chromosome transfer, whereby chromosomes in a human cell line are tagged with an antibiotic selectable marker; the cells are subsequently forced to
multinucleate, which facilitates the isolation of individual chromosomes and the creation of ‘microcells’. These are fused with mouse ES cells, and used
to generate mice via chimaera formation in blastocysts54,60,61,102,129.
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protein as extracellular plaques in the brain16,17. However, mouse
APP does not form the typical amyloid plaques found in human
AD. The reason appears to be that full-length mouse and human
APP proteins differ by 17 amino acids, notably at three key
residues within the central Aβ region that make the human
protein more ‘aggregatable’ than that of the mouse18. AD
researchers ﬁrst humanised this Aβ domain in 1996 by targeting
the three critical Aβ region codons, plus adding in a ‘Swedish’
familial AD mutation (causing two amino-acid substitutions
immediately adjacent to the β-secretase site in APP), which
resulted in enhanced Aβ production19. This came at a time when
creating humanised knock-in animals was unusual and only 5
years after the ﬁrst human APP mutations had been described in
early-onset familial AD16. Subsequently, other AD researchers
followed this same targeted humanisation approach for APP, but
adding in other well-deﬁned key familial AD mutations that affect
Aβ processing within the rest of the protein19–21. This has
resulted in extremely successful models of amyloid deposition
and some of these mice are currently among the most widely used
models in AD research, taken up by hundreds of labs world-
wide21. Recently, the widely used ‘NL-F’ mice (carrying both the
‘Swedish’ (NL) and ‘Iberian’ (F) APP mutations) have been
instrumental in showing that Aβ plaques can be seeded from
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and thus potentially also humans, highlighting the need to
carefully assess the risks for Aβ seed contamination via medical
procedures such as dura mater grafting22.
Fine-scale genomic humanisation of mouse genes can also be
used to address the question of how different alleles of a protein
of interest may play different roles in phenotypes. This is essential
for understanding the biochemical interactions relevant to
variation in human disease. To give an example, Apolipoprotein
E (APOE) is a protein involved in lipoprotein binding and
metabolism. Humans have three APOE alleles (-E2, -E3 and -E4)
that differ at residues 112 and 158. The APOE4 variant, which is
associated with susceptibility to cardiovascular disease and AD
risk, uniquely harbours Arg112 that causes another residue Arg61
to be exposed in the N-terminal domain enabling Arg61 to
interact with the C- terminal domain (-E2 and -E3 variants
neither have an exposed Arg61 nor such a domain interaction).
However, while the single mouse APOE allele has APOE4-like
Arg112, it lacks the human-speciﬁc Arg61 residue, lacks the
domain interaction, and instead preferentially binds to high
density lipoproteins, akin to the properties of human APOE3.
When mouse APOE was humanised solely at residue 61 (Thr61
to Arg61) its lipoprotein binding preference changed to very low
density lipoproteins (VLDLs) (akin to human APOE4), resulting
in cognitive deﬁcits and increased susceptibility to cardiovascular
disease, consistent with human APOE4-dependent clinical
features. In cardiovascular disease, increased binding of APOE4
to VLDLs leads to LDL receptor downregulation and increased
LDL plasma levels (i.e., ‘bad cholesterol’ that can build up in the
arteries)23; such an increase in LDL cholesterol is also a risk factor
for dementia, which is thought to alter the deposition and/or
clearance of Aβ, although the mechanism is not fully under-
stood24. These key ﬁndings highlight that a speciﬁc domain
interaction could be an important therapeutic target for
ameliorating impairments in APOE4 in humans25–27.
Humanising individual domains or exons. While introducing
individual human amino acids can be critical for modelling
human biology and pathology in mouse, this is not always
sufﬁcient. A dominant human pathogenic amino-acid mutation
in the VCP (valosine containing protein) gene results in inclusion
body myopathy associated with Paget disease of bone and fron-
totemporal dementia (IBMPFD) and ALS, but the same hetero-
zygous mutation has little effect in mice28. For many models,
the humanisation of speciﬁc stretches of amino acids or whole
protein domains is key to answering mechanistic questions.
One example that illustrates this comes from cancer research.
The core DNA-binding domain of p53 (TP53, transformation
related protein 53) is a hotspot for human cancer-associated
mutations, and, thus, of outstanding interest for drilling into
mechanisms of carcinogenesis. However, carcinogen-induced
mutations in mice do not affect the same residues as in
humans29. Therefore, to create mouse models suitable for
understanding cellular processes in human cancer, key exons 4–9
of mouse p53 (Trp53), which include the core DNA-binding
domain, were humanised, resulting in the translation of a chi-
meric mouse:human p53 protein30. Subsequent introduction of
human cancer-causing mutations gave new insights into how
p53 mutations cause disruption to DNA damage-sensing and
-response pathways31; and shed light on a human polymorphic
p53 variant that may be associated with increased cancer risk in
individuals of African descent32.
To study the effects of allelic variation on brain-derived
neurotrophic factor (BDNF) function, a region of 274 bp of the
human gene was inserted into the mouse Bdnf gene, including
one of two allelic variants: Val66 or Met6633. Val66 is the major
allele and also present in mouse, whereas Met66 in humans
reduces BDNF activity-dependent secretion, leads to structural
changes in the brain, and has been associated with psychiatric
disorders and stress. Comparison of these mice showed that
BDNF modulates competition in axonal branching33, which may
be involved in Met66 allele-associated neurological dysfunction.
Humanisation in this case, while providing a useful model to
study human variation, was not critical since others have created
a BDNF Met66 knock-in allele without humanisation to study
anxiety-related phenotypes to good effect34.
Two allelic variants of the OPRM1 gene have also been
modelled by humanisation of the ﬁrst coding exon of mouse
Oprm1, including one of two variants: the major 118A allele and
the minor 118G allele linked to alcoholism. The whole ﬁrst exon
was humanised because of the evolutionary divergence between
mouse and human in this region, although the requirement for
this extent of humanisation is untested. These humanised lines
showed that the 118G allele enhances ventral striatal dopamine
responses to alcohol, while also helping to reﬁne translational
studies by supporting the hypothesis that the 118G allele confers
an enhanced response to the opiate antagonist drug naltrexone; a
disputed link previously inferred from clinical studies35,36.
Continuing with the theme of preclinical translational research,
monoclonal antibodies are an essential tool of modern medicine,
but human and mouse epitopes often differ, which can be
problematic for in vivo testing of human monoclonal antibody
therapies in mouse. Humanisation of a mouse epitope can
overcome this problem. For example, a single exon of the Rankl
(Tnfsf11, tumour necrosis factor ligand superfamily, member 11)
gene was humanised to recapitulate the region of human RANKL
Fig. 1 Targeted genomic humanisation technologies. a HR in ES cells has been used to humanise loci up to ~200 kb (and beyond, using iterative targeting).
A plasmid, or BAC, targeting vector carrying human sequence ﬂanked by homology arms is transfected into ES cells by electroporation. Addition of Cas9:
sgRNA, generating a targeted double strand break, increases HR efﬁciency. An antibiotic resistance selectable marker is included to enrich for ES cells
harbouring the desired recombination. Selection cassettes are commonly ﬂanked by frt sites for later excision by FLP recombinase, leaving a single frt
genomic scar. b Recombinase-mediated cassette exchange (RMCE) can be used to humanise up to ~200 kb loci (can also be employed iteratively). In this
example, a landing pad is ﬁrst inserted at the target locus via HR (see part a), consisting of a selection cassette ﬂanked by heterotypic lox sites. The same
lox sites are inserted either side of the orthologous human locus within a BAC vector, which when electroporated into landing pad-harbouring ES cells will
recombine in the presence of CRE recombinase. Cas9:sgRNA pairs can subsequently be utilised to delete the mouse locus. As an alternative to FLP/frt
recombination, selection cassettes and other exogenous sequences can be ﬂanked by PiggyBac inverted terminal repeats (ITR), which when inserted at an
AATT recognition site, leave no genomic scar once excised with PiggyBac transposase. PiggyBAC transposition is less efﬁcient than FLP/frt recombination,
thus positive–negative selection cassettes (+/− s) such as HPRT (in HPRT−/− ES) or puroΔTK are used. c Introducing pathogenic mutations into
humanised alleles can be achieved by HR in zygotes using a ssODN (~150 bp) donor template combined with a locus-speciﬁc Cas9:sgRNA (no selection
required). A similar strategy can be used for small-scale humanisation projects (small genes or partial humanisation) using a long ssODN (<2 kb) as a
donor template and a pair of Cas9:sgRNAs. d Knock-in of large inserts (up to 200 kb) in both mouse and rat zygotes has been achieved by combining
Cas9:sgRNAs and short ssODN donors with hybrid homology at the break-points between donor and target site to facilitate HR
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targeted by the monoclonal antibody drug Denosumab, which
inhibits osteoclastogenesis and increases bone density; the
resulting mice were important for preclinical testing of the
efﬁcacy of the drug (non-humanised mice do not respond) in
treating speciﬁc bone disorders in humans37.
Partial humanisation can also be useful to recreate human-
speciﬁc nonsense peptides that result from frameshift mutations
that give rise to premature stop codons. For example, a splice-
acceptor site mutation in the human FUS (Fused in sarcoma)
gene that causes ALS leads to skipping of exon 14 and a
frameshift in the coding sequence of exon 15 (resulting in a 14
amino-acid frameshifted C-terminus), followed by a premature
stop codon. To recapitulate this mutation in the mouse, exon
15 of mouse Fus was humanised and the exon 14-skipping
splice-acceptor site variant was introduced. Humanising only
the splice site mutation would have resulted in a different and
signiﬁcantly longer frameshifted amino-acid sequence because
of the differences in exon 15 between human and mouse.
The partially humanised ‘FUS-Delta14’ mouse shows progressive
motor neuron degeneration in a dominant, toxic gain-of-function
manner and is currently one of the few physiological ALS
models available. Importantly, the 14 amino-acid human-speciﬁc
C-terminal frameshifted peptide has been instrumental in
developing an antibody, which can be used to track the disease-
causing protein in both mouse and human FUS-Delta14-
expressing cells to help understand motor neuron death in ALS8.
Partial genomic humanisation of mice also includes the
introduction of critical disease-causing non-coding DNA
sequences such as introns and regulatory elements. In a mouse
model of the recessive disorder familial dysautonomia, the
humanisation of a disease-causing intronic sequence resulted in
skipping of exon 20 of the IKAP transcript (IκB kinase complex-
associated protein) in the central nervous system, resulting in a
premature stop codon and protein depletion, which is also
observed in patients. While protein depletion in the mouse was
not sufﬁcient to recapitulate neurological phenotypes of the
disease, this model has been used for proof-of-principle studies
for developing new therapies aimed at restoring functional
protein levels38.
Thus, the humanisation of individual domains, regions and
introns to create chimeric transcripts and proteins has provided
the scientiﬁc community with highly informative mouse models
for understanding basic mechanisms and test systems for
translational research.
Fully humanised genes and networks within the mouse context.
The abundance of data from transgenic mice expressing human
cDNAs, or genomic sequences from plasmid or BAC vectors,
reassures that generally mouse and human proteins carry out
equivalent functions, and that fundamental processes such as the
recognition of splice boundaries are conserved between the two
species. The relatively few examples of full genomic humanisation
of mouse genes—i.e., the replacement of the entire protein coding
region, including introns, with the human sequence—generally
conﬁrm that the human genes can successfully replace their
mouse orthologues, albeit with sometimes minor changes in gene
expression.
Fully genomically humanised mice have been created to
recapitulate human biology and to achieve the greatest physio-
logical relevance in disease modelling or therapeutic develop-
ment, rather than to address questions of normal protein
function. For example, the mouse Apoe gene discussed above
has been fully genomically humanised in order to gain further
insight into the role of APOE in disease, including the effects of
the individual alleles. All three human APOE polymorphic
variants (APOE2, -E3 and -E4) were knocked-in to the mouse
locus (all three coding exons plus intervening introns), placing
them under the control of the mouse promoter. These models
have been widely used to better understand the molecular basis
for atherosclerosis and AD while also providing a means to test
therapeutics in a humanised context39–42. We note that such
models may be crossed in classical genetics approaches to provide
insights into human biochemical pathways. Humanised Apoe
mice, for example, have been crossed with Tau transgenic mice,
which revealed that APOE4 aggravates tauopathy independent of
amyloid-β pathology43.
Under certain circumstances, it may be necessary to humanise
multiple genes within a pathway or network to better model
human biology. Chimeric mice harbouring a human immune
system can be generated by engrafting immunodeﬁcient mice
with human haematopoietic stem cells; however, mouse cytokines
poorly cross react with human receptors and are inadequate to
support the maturation and function of these human immune
cells. Cytokines can be administered to the mice to overcome this
problem, but to achieve physiological expression levels and
distribution, several cytokine genes have now been fully
genomically humanised in mouse, and successfully support the
human cellular component of chimeric animals. Used in
combination, these knocked-in cytokine genes help improve the
development and function of human monocytes, macrophages,
and NK cells in the mouse environment44–48.
Moving onto translational research, a novel method for
production of high afﬁnity monoclonal antibodies against human
Complement C5a Receptor 1 (C5AR1), a therapeutic target for
various inﬂammatory conditions, was enabled by humanising the
complete mouse C5ar1 gene49, using neutrophils from C5AR1
humanised mice (expressing high levels of human C5AR1) to
immunise wild-type mice. C5AR1 humanised mice were subse-
quently successfully used for preclinical testing of the antibodies.
For pharmacokinetics analysis, a number of xenobiotic sensors
and drug metabolising enzymes have been fully humanised to
help predict human drug responses50–53.
Although there are relatively few published examples in which
entire mouse genes have been replaced with the human gene,
these genomically humanised animals are valid models for
understanding human biology and pathology, and have provided
tools and given insight that would not have been possible with
studying the mouse orthologues alone.
Genome humanisation for investigating complex disease loci.
The largest region of humanisation within the mouse genome
extends over tens of megabases of DNA within an almost com-
plete human chromosome 21 (Hsa21)54. In mice developed to
produce human antibodies, humanised regions are several
megabases in length55–57. In one of the ﬁrst large-scale genomic
humanisation studies of gene expression, the humanised region
was almost 200 kb long, located in the α globin gene cluster58. In
all these cases, perhaps surprisingly, phenotypes ranged from
relatively mild to apparently no different from wild-type mice
(other than for the production of human proteins). The largest
published region of humanisation currently comes from studying
the complex human chromosomal disorder Down syndrome,
which is an aneuploidy syndrome resulting from trisomy of
Hsa21. Modelling this disorder in mice poses a problem because
the content of Hsa21 is distributed over three syntenic regions on
mouse chromosomes 10, 16 and 1759. Thus, transchromosomic
mice (‘Tc1’ and others) were created via microcell-mediated
chromosome transfer of Hsa21 into mouse embryonic stem (ES)
cells and subsequent production of chimeric mice via blastocyst
injection, followed by breeding of chimeras for germline
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transmission of the human chromosome54,60,61. Tc1 mice, which
carry an extra > 42Mb of human DNA, recapitulate many fea-
tures of Down syndrome, most of which are fairly mild (on the
genetic backgrounds studied) and include neurological, cardiac
and mandible phenotypes54. However, Tc1 mice lose the human
chromosome stochastically, more from rapidly dividing cells such
as those in the thymus, than, say those in the brain (where ~ 67%
of cells retain the human chromosome), and the resulting
mosaicism probably contributes to the mildness of the
phenotypes54.
Efﬁcient production of human monoclonal antibodies from
human immunoglobulin IgG light and heavy chain knock-in
mice has been achieved, by two different groups independently,
by megabase-sized knock-in of the variable regions of both heavy
and light chain human IgG loci55–57. Both groups implemented
iterative targeting of kilobase-sized segments in ES cells using
BAC vectors; one group used a homologous recombination (HR)
strategy, while the other utilised recombinase-mediated cassette
exchange (RMCE) alongside the PiggyBac transposase system for
megabase-sized scarless editing. Remarkably, in both approaches,
these knock-in mice show no functional impairments in their
immune systems, which is in contrast to previous non-targeted
humanisation efforts. They have been used for testing therapies
against HIV-1 (human immunodeﬁciency virus-1) and develop-
ing human therapeutic antibodies to treat diabetes55–57,62,63.
More recently, an alternative one-step approach was devised to
knock-in pre-arranged human heavy chain sequences (~ 1.9 kb;
directly into zygotes) for generation of antibodies against critical
HIV-1 epitopes64.
Genomic humanisation of large complex loci has shed light on
important non-coding regulatory sequences, which would have
been difﬁcult in conventional mouse models. Humanisation of
the α globin gene cluster, via recombinase-mediated genomic
exchange (RMGE), was undertaken to study gene expression
from this clinically important region and represented a proof-of-
principle that humanising large genomic loci is possible. One
outcome of this research was the ﬁnding that globin gene
expression levels differ between the humanised mice and wild-
type animals. Further dissection of the underlying cause showed
that the HS-40 element in this cluster was critical for α globin
gene expression within the human, but not the mouse locus58,65.
The surprising conclusion from reports of mice in which large
regions of the genome have been replaced or human sequences
added, is that phenotypes are generally mild without an apparent
effect on mouse welfare. This is at least true for wild-type loci.
However, even in the largest genomic humanisation effort
reported to date, the Tc1 mouse model of Down syndrome,
<1% of the genome is human DNA.
Lessons learned so far for humanisation strategies
The rules of the genome are not fully understood, nor are the full
phenotypic consequences of creating mice with human genomic
DNA. However, although genomically humanised mice are rela-
tively few, it is clear that they can give insight into biology and
pathology that cannot necessarily be gained from conventional
mouse models. Advances in genome engineering technologies,
including CRISPR (clustered regularly interspaced short palin-
dromic repeats (CRISPR)-Cas approaches (Box 1), mean that
making humanised models is easier and faster than ever before—
although still not a conventional route—such that even when the
speciﬁcs of mouse:human transcript or protein differences are
unknown, humanisation should be considered. However, the
design of a humanisation strategy is far from routine, and a key
question remains: how far to humanise (summarised in Fig. 2)?
To keep things simple or go full scale?. The decision whether to
humanise just a codon, just a domain, just the coding region, or
to go full scale and include introns and ﬂanking regulatory
regions depends on the questions being asked, as we have dis-
cussed above. Most genomically humanised mice in the literature
have ﬁne-scale changes within the coding sequence that result in
chimeric human:mouse proteins, facilitating the study of critical
aspects of protein biochemistry, without greatly altering mouse
genome architecture.
To work with models that contain full-length human genes,
perhaps in trying to produce human-speciﬁc splice patterns and
regulation from intronic sequences, human genomic architecture
How far does the 
promoter extend? 





*   *        *
Fine scale residue 
humanisation
Full humanisation





Mouse gene of interest
Protein
Fig. 2 How far to humanise. A summary of considerations when deciding on the extent of targeted genomic humanisation for a given gene of interest. Dark
green boxes represent exons, lines between exons are introns, light green boxes are UTRs and blue regions represent humanisation. a Partial humanisation
typically involves humanising speciﬁc residues and/or domains of interest. Fine-scale humanisation of speciﬁc amino-acid residues can be performed in
isolation if they have known biochemical differences from mouse to human, or if only a small number of residues need to be altered to achieve a human
protein sequence. Speciﬁc domains or exons can be humanised if, for example, they are known to be critical for human disease. Examples of translated
protein products are given. b Full humanisation involves humanising the whole gene, including introns, to attain translation of the full human protein,
potentially including human-speciﬁc splicing patterns, and for maximum translational potential. 5ʹ and 3ʹ-UTRs, promoters, and other regulatory sequences
can be included, on a case-by-case basis, if understanding of gene regulation is the question at hand, if gene clusters are to be humanised or if pathogenic
mutations fall within such ﬂanking regions
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has to be introduced. Mice have on average of ~ 2.4 splice
isoforms per gene, whereas humans produce ~ 3.4 isoforms per
gene66 and individual splice isoforms can be disease causative.
For example, the isoform ratios of TAU, encoded by MAPT, are
critical in causing frontotemporal dementia, and while a
genomically humanisedMAPT mouse has not yet been described,
encouragingly a human BAC transgenic recapitulates human
MAPT splicing in mouse67. Thus, if the full repertoire of human
splice isoforms is required, then full-scale humanisation across
the gene of interest could be attempted.
Exclusion of introns, which might help to keep things simple in
a humanisation strategy, can potentially be disruptive. For
example, when the xenobiotic sensor PXR (Pregnane X receptor)
was originally humanised, some introns were excluded—it was
later discovered that this caused a mis-splicing event as a result of
exons 7 and 8 fusion, leading to creation of a new splice-acceptor
site and variant whereby exon 5 spliced to exon 8. The gene was
subsequently fully humanised to eliminate this variant52,53. Thus,
and perhaps not surprisingly, in at least some cases, maintaining
the human genome architecture is likely critical for normal gene
expression in mouse.
We note that in moving towards translational research, the
presence of the full-length human transcripts and proteins
maximises the potential to test therapeutics relevant for use
in humans. An excellent example of this comes from the need
to determine the optimal dose of human antisense oligomer
(ASO) therapies against the human rather than mouse mRNA
sequences, because in the clinic the oligomer must bind to
the human sequence; as, for example, in ASOs that modulate
APOE levels42.
Considering ﬂanking regulatory sequences. If an investigation
warrants the genomic humanisation of an entire mouse gene,
which is coding regions and internal introns, the decision over
how far to extend into the 5ʹ and 3ʹ regions currently relies largely
on a combination of limited information, expediency, and
guesswork. It is essential to look closely at how far the gene of
interest extends upstream and downstream, as apart from dif-
ferent transcripts, the gene may in addition produce alternative 5ʹ
and 3ʹ exons that contain different untranslated regions (UTRs),
which may affect gene regulation. However, even with this
information, generally too little is known about the regulatory
sequences within most genes to judge whether to humanise only
from the ﬁrst ATG to the last stop codon or to humanise from the
start of the ﬁrst 5ʹ UTR (if known) to the end of the last 3ʹ UTR (if
known) of alternative transcripts. For single genes, a conservative
approach is to humanise between outermost known start and stop
codons only. A riskier approach—but one that may result in more
faithfully recapitulated human gene regulation—is to include the
human UTRs. However, currently there is insufﬁcient informa-
tion to reliably predict the outcome of this strategy and to make
generalisable rules.
A critically important feature for gene regulation is the gene
promotor, but currently no good spatial deﬁnition of the
promotors of most genes is available. Often the best that
researchers can do is to assume that the CG-rich region upstream
of a gene includes the promotor, and to look carefully for
transcription factor binding sites within or nearby this genomic
sequence. In fact, so far targeted humanisation of most single
genes has not included promoter sequences, just in case critical
promoter–enhancer interactions were to be disrupted. Further-
more, some regulatory elements may control genes long distances
away68, for example, in human and mouse the 1Mb-distal ZRS
enhancer for Sonic hedgehog (Shh) is critical to limb-speciﬁc Shh
expression69.
One potential limitation of genomic humanisation strategies
that include the promotor regions is that even though human and
mouse transcription factors are conserved, orthologues do not
necessarily have identical amino-acid sequences or recognise
identical motifs. Therefore, mouse proteins might not correctly
regulate the transcription of human genes. This problem was
addressed to some extent by the Tc1 mouse model of Down
syndrome that carries Hsa21, mentioned above. The researchers
investigating transcription factor binding found that mouse
transcription factors did indeed bind to the human cognate sites,
despite the sequences often being slightly different from the
mouse orthologous sites. This result may allay some fears about
introducing human promoters for human genes into the mouse
cellular environment70. This result was in part corroborated by a
recent RNA deep sequencing study of Hsa21 in both the Tc1
mouse and in human cells;71 speciﬁcally, mouse trans acting
factors (such as transcription factors) appeared responsible for
regulating humanised gene expression. This was evident since
humanised gene expression levels in mouse closely correlated
with levels of the mouse orthologous gene, and not the human
gene in human cells71, in contrast to ﬁndings of the earlier study
that suggested human expression levels were maintained70.
Importantly for humanisation studies, splicing patterns of genes
on the humanised chromosome in Tc1 mice closely recapitulated
splicing patterns in human cells, even in human non-coding
genes that do not have mouse orthologues71, indicating that
regulation of splicing is intrinsically sequence dependent and that
splicing machinery is well conserved between mouse and human.
Finally, expediency comes into play in targeting strategies
when humanising a sequence might disrupt important mouse
features. In a project we have underway, we ﬁnd that the 3ʹ-UTR
of a mouse gene of interest overlaps the 5ʹ-UTR of the adjacent
gene, whereas in the human genome the two orthologues are
separated by several kb. In this case, our humanisation strategy
extends only to the stop codon of the gene of interest, and no
further, to ensure that the mouse 3ʹ-UTR is not disrupted, and we
do not inadvertently alter the regulation of the downstream gene.
Genomic humanisation of sequences that do not exist in
mouse. Approximately 1% of human genes do not have a mouse
orthologue and vice versa72, and some of the 99% of homologous
protein coding genes may exist in different copy numbers in the
two species. For example, mice have a single Smn gene encoding
the survival motor neuron protein, but humans have SMN1 and
up to four copies of its paralogue SMN2. SMN1 and SMN2 are
almost identical but a single-nucleotide change in exon 7 of
SMN2 results in ~80% of its transcripts producing an unstable,
truncated protein and only ~20% of SMN2 mRNA encoding
functional protein. This becomes critically important when
studying type 1 spinal muscular atrophy (SMA), a recessive dis-
ease with an incidence of ~1 in 10,000 depending on the popu-
lation, which arises from mutation in SMN1. Left untreated,
children with SMA die before 4 years of age from respiratory
failure due to lower motor neuron death73. This form of SMA has
been modelled by strategies that include targeting human SMN2
into Smn null mice, for example, to recapitulate the human
condition (ref. 74 and papers therein).
We wish to raise for consideration the following (so far
hypothetical, but possible) scenario: where human paralogs have
taken on different functions, but only one mouse homologue
exists, humanising the mouse gene may potentially only produce
a protein that functions as a single human paralog, leaving the
remaining functions of the other human paralog(s) absent from
the mouse.
Triplet (and larger) repeat expansion diseases have not been
found in mice, and yet are a well-known cause of neuromuscular,
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neurodegenerative and other disorders in humans. Genomic
humanisation is a route to model these disorders in mice; for
example, in humans, a CAG expansion in exon 1 of the androgen
receptor (AR) gene results in a polyglutamine (polyQ) tract in the
protein and can lead to spinal bulbar muscular atrophy (SBMA).
Mouse Ar exon 1 has signiﬁcant sequence divergence from
the human orthologue and so a model was created that
humanised 1340 bp of exon 1, including a human-speciﬁc 113-
residue polyQ-tract. This has proven successful in uncovering
disease mechanisms and developing therapeutics for SBMA75–82.
Huntington disease (HD) is another polyQ-expansion neuro-
degenerative disease, which has been modelled extensively via
BAC transgenesis (producing fast, neurodegenerative pheno-
types) and via knock-in strategies (slowly progressive pheno-
types). Humanised knock-in HD models consist of humanisation
of exon 1 of the mouse Huntington (Htt) gene, which includes a
pathogenic polyQ-tract adjacent to a polypurine tract83–87 (both
of these features show poor conservation between mouse and
human). Such mice are available as an allelic series derived from
natural expansion of the CAG repeat in vivo, ranging from those
with mild molecular changes to those with progressive beha-
vioural and motor dysfunction. Non-humanised knock-in HD
mice (expanding the mouse polyQ tract alone) have also been
generated with similar phenotypes; nevertheless, humanised
models have been widely used to gain insights into disease
pathophysiology, including characterising the timing of early
neuropathological changes, identifying posttranslational modiﬁ-
cations crucial to mutant HTT pathology, and omics proﬁling to
understand repeat length-dependent dysfunctions88–91. Humani-
sation has also allowed successful therapeutic testing of gene
editing strategies targeting human exon 1 with the aim of excising
the repeat expansion92.
When the genomic context of a disease-causing mutation is
entirely speciﬁc to humans, humanisation is the only option.
For example, an SVA retrovirus insertion into the 3ʹ-UTR
(located in exon 10) of the human FKTN (FUKUTIN) gene
causes Fukuyama muscular dystrophy93. SVA retrotransposons
are hominid speciﬁc and do not exist in mouse. Therefore, the
whole of mouse Fktn exon 10 was humanised, with and without
the SVA insertion, to replicate any sequence-speciﬁc effects the
insertion may have on the host gene. Indeed, this turned out to
be important as the SVA insertion caused an abnormal 3ʹ splicing
pattern in both the mouse model and human patients—leading
to severely reduced protein expression. The humanised model
mimics some—but not all—of the human disorder phenotype,
and has been useful for understanding disease mechanism. This
example demonstrates that introducing a wider genomic context
to the disease-causing mutation can be essential for replicating
pathogenic mechanisms93.
In genetically complex disorders, differences between mouse
and human might be so prominent—both in genomic context
and biology—that a considerable investment in understanding
the locus or loci of interest has to be made before a detailed
approach to modelling can be developed. β-Thalassaemia in
humans results from mutations in the β globin locus that lead to
a reduction of functional adult β-globin protein levels. Simple
replacement of the two mouse genes for adult β globin with
the single human β globin gene containing an intronic causative
β-thalassaemia βIVS-2-654 mutation led to classic signs of
β-thalassaemia intermedia in heterozygous mice94. These mice
have been used to test therapies that either block (using splice-
switching oligonucleotides) or correct (via gene editing) the
cryptic splice site introduced by the mutation95,96. However,
divergence in sequence (four genes in mouse, ﬁve in human) and
timing of embryonic-to-foetal-to-adult β-globin expression
between mouse and human complicates modelling of both
β-thalassaemia major and sickle β-thalassaemia—severe, recessive
forms of anaemia characterised by a lack of functional adult
β-globin. Human patients survive untreated for some time
postnatally, supported by foetal β-globins, which do not fully
switch to adult β-globins until 1 year of age. Simply knocking-out
mouse adult β-globins fails to model these recessive anaemias
because mice lack a bona ﬁde foetal haemoglobin and the knock-
out mice are non-viable because mouse foetal liver erythropoiesis
depends on adult β-globins. Thus, to model human recessive
thalassaemias, a bespoke humanised approach was required that
involved the replacement of the mouse adult β globin genes with
a delayed foetal-to-adult haemoglobin-switching transgene
enabling survival to birth97,98. Postnatal survival was later further
improved by introducing a ‘hereditary persistence of foetal
haemoglobin’ mutation within the human γ-globin gene
component99,100. Thus, gaining a detailed understanding of the
architectural and expression differences between mouse and
human loci may be necessary to inform how best to introduce
human sequences into a mouse genome to obtain the most
informative results.
Humanising entire chromosomes. The genome contains features
beyond the primary genetic sequence that may affect humanisa-
tion strategies. A possible example of this arises in the Tc1 mouse
model of Down syndrome, which stochastically loses Hsa21 over
time, resulting in mosaic mice54. This may be due to the cen-
trosomes of the mouse cells not properly recognising or inter-
acting with the centromere of the human chromosome. New
types of human artiﬁcial chromosomes (HACs), including those
with mouse centromeric sequences, are likely to give greater
stability to human chromosome-sized regions in mouse101.
Similar to the Tc1 model, microcell-mediated chromosome
transfer was employed to create mice harbouring human mini-
chromosomes carrying the entire immunoglobulin heavy and
kappa light chain loci, combined with knock-out of the ortho-
logous mouse loci, to successfully express fully human anti-
bodies102. Of note in this case, minichromosomes were found to
be mitotically and meiotically unstable and mice had impaired B-
cell development and partial immune deﬁciencies.
Full genomic humanisation is not always the best strategy.
Finally, it may be beneﬁcial not to humanise speciﬁc domains
when they, for example, have important functions in determining
cellular localisation. In humanisation of both Prnp (Prion pro-
tein) and Ctla4 (cytotoxic T lymphocyte-associated 4), the mouse
signal peptide sequence in each of these genes was retained, to
avoid potential problems with translocation to the cell membrane;
since signal peptides are cleaved, this should have no effect of the
biochemistry of the mature protein103,104.
Unexpected effects. The phenotype of a genetic mouse model—
transgenic or genomically humanised—is not always predictable,
but when unexpected outcomes arise, such models can provide
valuable insight from studying the mechanism of why the
observed outcome is different from expectation. As an example,
to model myotonic dystrophy, the 3ʹ end of the Dmpk (dystrophia
myotonica protein kinase) gene was humanised, including the
addition of 84 CTG repeats in the 3ʹ-UTR, which leads to
pathology in humans. In Dmpk-humanised mice, however, this
repeat number failed to produce a pathogenic phenotype.
Nevertheless, this model gave important insight into the somatic
instability of the repeats, and provided evidence that repeat sta-
bility is associated with the activity of mismatch–repair (MMR)
machinery105.
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Similarly, in larger-scale humanising of the introns and exons
of a gene, the mouse environment (chromosomal or cellular) may
cause unexpected phenotypes. Currently, this is unpredictable
and must be assessed on a case-by-case basis, but does not
preclude working with such animals. For example, the large-scale
humanisation of the α globin locus (knocking-in 117 kb of human
DNA, deleting 85 kb of syntenic mouse DNA) resulted in
signiﬁcantly reduced expression (40% of mouse α globin
expression levels) of α globin from the humanised locus, but
the developmental pattern of α globin expression was retained
and histological markers were normal, allowing evaluation of the
mechanistic outcomes of point and indel mutations at this
locus58.
Genome architecture can be disrupted by scars in the genomic
landscape (i.e., introduction of exogenous sequences that could,
for example, disrupt promoters or enhancers and affect gene
regulation). An experiment to humanise rhodopsin included
fusion of green ﬂuorescent protein (GFP) at the C-terminal end,
in order to visualise Rhodopsin-expressing cells in the retina with
high sensitivity; however, the GFP fusion generated a recessive
allele, unexpectedly causing death of rod photoreceptor cells,
thereby providing a useful, even though unintended, model for
retinal neurodegeneration106. In the same study, other humanised
alleles were generated that also included the presence of
recombinase recognition lox sites ﬂanking Rhodopsin–GFP,
which signiﬁcantly reduced translation of the gene, and further
exacerbated retinal degeneration. Thus, introduction of exogen-
ous sequences into a locus should be carefully considered and
evaluated for unintended effects. Certain forms of genomic
scarring, such as frt sites left behind from exogenously inserted
selection cassettes (needed during genome engineering in ES cells;
see Fig. 1a), can now readily be avoided by using the PiggyBac
transposase system or CRISPR/Cas9 targeting in zygotes (which
does not require selection, and therefore leaves no genomic scar)
(Fig. 1b, c).
Another unexpected, but informative, outcome of humanisa-
tion comes from the Tc1 mouse model, which was produced to
understand Down syndrome phenotypes, but in fact also gave
insight into the expression of primate-speciﬁc repeats. Over 50%
of the human genome is derived from repetitive elements, mostly
from transposable elements that can act as regulatory DNA and
whose activity is controlled by several different mechanisms.
Placing Hsa21 into the mouse nuclear environment resulted in
transcriptional activation of transposon-derived human regula-
tory regions, which could potentially inﬂuence gene expression of
nearby transcripts on this chromosome; among other results, this
highlighted the latent regulatory potential of human-speciﬁc
elements107.
Importantly, we also wish to highlight the need to work with
a wild-type genomically humanised animal as a control, where
possible, when studying genomically humanised mutants. This
is to ensure that unexpected phenotypes that derive from the
human DNA per se are distinguished from those associated
with the mutation, in particular when introducing many kb- or
Mb-sized stretches of DNA.
When far is too far. Just as important as the technical and
strategic considerations regarding genomic humanisation, are the
ethical issues—how far can humanising the mouse genome go
while still having a mouse? This is an unresolved question that
was discussed in a report by the UK Academy of Medical Sciences
(‘Animals containing human material’, 2011), which at the time
cautiously concluded there were no new ethical challenges.
However, since then the ﬁeld of genome editing has exploded
with new technologies and these considerations may have to be
revisited in the near future. This issue is of course also pertinent
to the mouse:human cellular chimeras that have been made for
many years with the purpose of studying the immune system and
which are now also being created, for example, to better under-
stand brain function and dysfunction108,109.
Genomic humanisation going forward
The technology for targeted genomic humanisation of the mouse
requires further development to streamline approaches and to
simplify working with long and challenging sequences such as
expanded repeats. In that regard, CRISPR/Cas systems are
changing rapidly, offering great potential for genomic humani-
sation that is only just beginning to be realised. Modiﬁed Cas9
variants, including base editors and variants with alternative
protospacer adjacent motif speciﬁcity, now permit more precise
editing than ever before110,111, whereas structural or copy num-
ber variants can be modelled in mice following humanisation of
any given gene112.
Nevertheless, many technical challenges remain. For example,
several important human disease genes are now known to
undergo repeat-associated non-ATG (RAN) translation—often
producing peptides in all three or even all six reading
frames (when taking into account translation in the reverse
direction)113. Producing humanised mouse models that carry
stable repeats to understand associated pathomechanisms is not
yet routine. Furthermore, for at least some of these repeats the
ﬂanking sequence contexts may be important for disease mani-
festation114, meaning that, in addition, the entire human gene
sequence has to be knocked-in as a control.
Even in cases of relatively straight forward humanisation of
a single wild-type gene, as described in the examples above, it
is not always clear how far one should extend genomic huma-
nisation in order to most faithfully recapitulate human gene
expression in a mouse context. In eukaryotes, for example, it
largely remains to be determined where and how transcription
terminates, which may be many bp or even kb beyond the
polyadenylation signal in a transcript. Transcription terminator
proteins are involved in releasing mRNAs and RNA Polymerase
II from each other115,116, and this is coupled to cleavage and
polyadenylation of the 3ʹ end of mRNAs and associated with
the effects of transcription boundary-associated RNAs, which
include terminus-associated RNAs117. Termination can occur at
different sites 3ʹ of the polyadenylation signal, and usually it is
not known how far to humanise beyond the 3ʹ-UTR of a gene.
Yet, these sequences can have profound effects on transcription
and translation118.
Similarly, codon usage is clearly important for translation,
affecting, for example, mRNA stability, ribosome binding, mRNA
processivity, and other phenomena119. However, as mouse and
human are only separated by 75 million years of evolution, it is
assumed that codon usage will have similar effects in both species,
but this may not be the case for speciﬁc genes.
Thus, the optimal strategy for genomic humanisation is likely
to be only discernible on a gene-by-gene basis following con-
siderable prior investment in gathering data on human gene
expression in human cells and tissues. However, existing models
clearly show the utility of working with current knowledge, and
have in fact helped to ﬁnd new regulatory sequences that would
have been hard to ﬁnd otherwise2,58,65.
In making genomically humanised mice, unexpected insights
about coding regions can be gained; for example, for some
pathogenic human alleles, such as the A53T mutation in SNCA
that causes Parkinson’s disease, the human disease variant is the
wild-type sequence in the mouse. This well-known phenomenon
occurs at least in some cases because of compensatory
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evolutionary changes at speciﬁc sites elsewhere in the gene/
protein120,121. Thus, humanisation of the complete gene, with the
normal human sequence (aberrant in mouse) and the disease
human allele (wild-type in mouse) may provide a route to
studying phenotype. Alternatively, the evolutionary compensa-
tion of variant residues could occur within other genes that
interact with SNCA, meaning that multiple genes might have to
be humanised to yield a phenotype of interest.
In modelling human disease in an age of personalised medi-
cine, humanisation of a single allele will not be sufﬁcient to
address the great variability between individuals, including
response to treatment and clinical trajectories. This remains a
challenge for mouse modelling in general, not just for creating
genomically humanised models. Furthermore, humanisation of a
single gene may not be sufﬁcient to understand biology or
pathology—particularly when protein complexes or
ligand–receptor interactions are involved. Thus, at a minimum,
the between-species conservation of these interactions should be
considered. Future approaches to humanised mouse models may
lie in humanising entire networks or pathways.
Genome wide association studies have identiﬁed thousands of
disease risk loci in the human genome, the majority of which lie
in non-coding regions. Modelling non-coding variants in animals
is challenging, due to the lack of evolutionary sequence con-
servation in many non-coding regions. Recently, liver-associated
expression quantitative trait loci (eQTL) were identiﬁed via
screening in hepatocyte cell lines derived from a cohort of healthy
volunteers122, as part of a study to identify lipid-functional genes
and variants, and to better understand human complex traits. In
the same study, one of the lead eQTLs (rs2277862; T) was
modelled in mice via CRISPR-Cas9 mutagenesis in zygotes,
including humanisation of four surrounding nucleotides such
that the wider region became identical to the human sequence,
leading to signiﬁcant reduction in expression of the nearby
CPNE1 gene, whose function is still to be determined. Thus,
technological advances in genome engineering combined with the
ever improving understanding of genomic architecture render
genetic modelling of non-coding variants an exciting future
prospect123.
The development of CRISPR/Cas technologies means that the
mouse is no longer exceptional and in fact data on genomically
humanised rats and pigs are already emerging124,125. Future
humanisation strategies may thus involve a range of model
organisms, which inevitably means new ethical boundaries will
have to be deﬁned. Finally, to facilitate a reduction in the use of
animals for research purposes, humanised mouse models can and
should be studied in parallel with human tissue samples and
human in vitro models, which will at the same time further help
in obtaining a more complete picture of human biology and
pathology.
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